, Volume 46, Issue 2, pp 231–238 | Cite as

Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis

  • Luca Rinaldi
  • Antonio Ascione
  • Vincenzo Messina
  • Valerio Rosato
  • Giovanna Valente
  • Vincenzo Sangiovanni
  • Rosa Zampino
  • Aldo Marrone
  • Luca Fontanella
  • Nicolina de Rosa
  • Pasquale Orabona
  • Carmela Buonomo
  • Antonio Chirianni
  • Luigi Elio Adinolfi
  • Guido Piai
Original Paper



The aim of this study was to evaluate the effects of antiviral therapy on liver stiffness measurement (LSM).


Two hundred HBV patients were enrolled from four hospital centers in southern Italy; median age was 50.7 (25–75) males were 68%; 171 patients underwent to liver biopsy and 200 patients had LSM at baseline and 189 at the end of follow-up. One hundred and forty-nine patients were treated with nucleos(t)ide analogs, while 51 patients were untreated. The cutoffs of the LSM, related to the fibrosis stages, were as follows: non-advanced fibrosis ≤ 8.1 kPa and advanced fibrosis ≥ 8.2 Kpa.


At baseline, the median value of LSM was 14.1 kPa for advanced fibrosis/cirrhosis and 6.9 kPa for non-advanced fibrosis. LSM was performed at 24 months from the start of therapy. The treated patients (68% received Entecavir and 32% Tenofovir) showed a decrease in liver stiffness measurement of 1.5 kPa (p < 0.001) in non-advanced fibrosis and of 6 kPa (p < 0.001) in advanced fibrosis/cirrhosis. In the patients not undergoing antiviral treatment, no statistically significant change of the LSM was observed (p = 0.26). A logistic binary regression model showed that the only independent factor associated with a significant change in the LSM was the liver stiffness value at baseline (odd ratio 2.855; 95% CI 1.456–5.788; (p = 0.007).


Long-term antiviral therapy induced a significant reduction of liver stiffness measurement and this result may be related to the reduction of liver fibrosis.


Transient elastography Liver stiffness Hepatic fibrosis Chronic hepatitis B Antiviral therapy 



AITF (Italian Association of Liver Transplanted Patients)—Delegation of Caserta (Italy) and Stefania Milione MD, Università degli Studi della Campania “Luigi Vanvitelli”, for the cooperation in editorial assistance.


Financial support, Progetto SATTE—Campania Region (DGR 1389/2009).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29. Scholar
  2. 2.
    Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66:1296–313. Scholar
  4. 4.
    Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label followup study. Lancet. 2013;381:468–75. Scholar
  5. 5.
    Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274–6. Scholar
  6. 6.
    Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013;28:912–23. Scholar
  7. 7.
    Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1–3. Scholar
  8. 8.
    Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int. 2014;34:91–6. Scholar
  9. 9.
    Rinaldi L, Valente G, Piai G. Serial liver stiffness measurements and monitoring of liver-transplanted patients in a real-life in clinical practice. Hepat Mon. 2016;16:41. Scholar
  10. 10.
    Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new non invasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Kettaneh A, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Lédinghen V. Features associated with success rate and performance of Fibroscan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007;46:628–34. Scholar
  12. 12.
    Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2014;20:14568–80. Scholar
  13. 13.
    Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208. Scholar
  14. 14.
    Rinaldi L, Restivo L, Guerrera B, Zampino R, Marrone A, Pasquale G, Zappalà R, Nevola R, Adinolfi LE. Hepatic steatosis and necro-inflammatory activity overestimate liver stiffness by Transient Elastography in staging liver fibrosis in chronic hepatitis C. J Hepat Res. 2014;3:01–6.Google Scholar
  15. 15.
    Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56:968–73. Scholar
  16. 16.
    Kim JH, Kim MN, Han KH, Kim S. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int. 2015;35:1103–15. Scholar
  17. 17.
    European Association For The Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(17):30185. Scholar
  18. 18.
    Boursier J, Zarski JP, de Ledinghen V, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Calès P. Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91. Scholar
  19. 19.
    Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29:242–7. Scholar
  20. 20.
    Bedossa P. Reversibility of hepatitis B cirrhosis after therapy: who and why? Liver Int. 2014;35:78–81. Scholar
  21. 21.
    Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, Chon CY, Ahn SH, Kim SU. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7:1–7. Scholar
  22. 22.
    Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–9. Scholar
  23. 23.
    Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22:8314–21. Scholar
  24. 24.
    Cai YJ, Dong JJ, Wang XD, Huang SS, Chen RC, Chen Y, Wang YQ, Song M, Chen YP, Li Z, Zhou MT, Shi KQ. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B. J Viral Hepat. 2017;24:1005–15. Scholar
  25. 25.
    Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol. 2013;28:1842–8. Scholar
  26. 26.
    Castéra L, Bernard PH, Bail B, Foucher J, Trimoulet P, Merrouche W, Couzigou P, Lédinghen V. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011;33:455–65. Scholar
  27. 27.
    Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–93. Scholar
  28. 28.
    Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776–83. Scholar
  29. 29.
    Lim SG, Cho SW, Lee YC, Jeon SJ, Lee MH, Cho YJ, Kim SS, Kim YB, Seok JY, Cheong JY, Kim JH. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B. Hepatogastroenterology. 2011;58:539–45.PubMedGoogle Scholar
  30. 30.
    Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chu SH, Chan FK, Sung JJ, Chan HL. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther. 2011;16:165–72. Scholar
  31. 31.
    Kim JK, Ma DW, Lee KS, Paietk YH. Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents. J Korean Med Sci. 2014;29:570–5. Scholar
  32. 32.
    Andersen ES, Weiland O, Leutscher P, Krarup H, Westin J, Moessner B, Konopski Z, Frigstad SO, Kjær M, Christensen PB, Weis N. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol. 2011;46:760–6. Scholar
  33. 33.
    Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014;9:1–8. Scholar
  34. 34.
    Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int. 2014;34:1216–23. Scholar
  35. 35.
    Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-Year prospective study. PLoS ONE. 2014;9:1–8. Scholar
  36. 36.
    Jang W, Yu SI, Sinn DH, Park SH, Park H, Park JY, Jeon TJ, Oh TH, Shin WC, Choi WC. Longitudinal change of liver stiffness by transient elastography in chronic hepatitis B patients treated with nucleos(t)ide analogue. Clin Res Hepatol Gastroenterol. 2014;38:195–200. Scholar
  37. 37.
    Fung J, Lai CL, But D, Hsu A, Seto WK, Cheng C, Wong DK, Yuen MF. Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. Hepatol Int. 2010;4:716–22. Scholar
  38. 38.
    Viganò M, Massironi S, Lampertico P, Iavarone M, Paggi S, Pozzi R, Conte D, Colombo M. Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol. 2010;22:180–4. Scholar
  39. 39.
    Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, Asselah T, Boyer N, Lada O, Castelnau C, Martinot-Peignoux M, Valla DC, Bedossa P, Marcellin P. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012;32:612–21. Scholar
  40. 40.
    Kim BK, Fung J, Yuen MF, Kim SU. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol. 2013;19:1890–900. Scholar
  41. 41.
    Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241–9. Scholar
  42. 42.
    Warren-Gash C, Childs K, Thornton A, Bhagani S, Demma S, Srivastava A, Leen C, Agarwal K, Rodger AJ, Sabin CA, Joint UK. CHIC and liver transplant advisory group. Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. Infection. 2017;45:215–20. Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Luca Rinaldi
    • 1
  • Antonio Ascione
    • 4
  • Vincenzo Messina
    • 2
  • Valerio Rosato
    • 1
  • Giovanna Valente
    • 3
  • Vincenzo Sangiovanni
    • 5
  • Rosa Zampino
    • 1
  • Aldo Marrone
    • 1
  • Luca Fontanella
    • 1
  • Nicolina de Rosa
    • 7
  • Pasquale Orabona
    • 6
  • Carmela Buonomo
    • 6
  • Antonio Chirianni
    • 5
  • Luigi Elio Adinolfi
    • 1
  • Guido Piai
    • 3
  1. 1.Department of Medical, Surgical, Neurological, Metabolic, and Geriatric SciencesUniversità degli Studi della Campania “Luigi Vanvitelli”NaplesItaly
  2. 2.Infectious Diseases C.O. UnitAORN S. Anna and S. SebastianoCasertaItaly
  3. 3.Department of Medical SciencesAORN S.Anna e S. SebastianoCasertaItaly
  4. 4.Department of Internal Medicine, Centre for Liver DiseasesOspedale Buon Consiglio FatebenefratelliNaplesItaly
  5. 5.Department of Infectious Emergencies and Infectious DiseasesAzienda Ospedaliera Dei ColliNaplesItaly
  6. 6.Department of ServiceAORN S. Anna and S. SebastianoCasertaItaly
  7. 7.Department of Diagnostic ServiceAzienda Ospedaliera dei ColliNaplesItaly

Personalised recommendations